nivolumab + ipilimumab + cabazitaxel + carboplatin

This regimen is an **investigational four-drug combination** comprising two immune checkpoint inhibitors (nivolumab and ipilimumab), a taxane chemotherapy (cabazitaxel), and a platinum-based chemotherapy (carboplatin). - **Nivolumab** is a monoclonal antibody targeting programmed cell death protein 1 (**PD-1**), blocking this checkpoint to enhance anti-tumor T-cell activity. - **Ipilimumab** is a monoclonal antibody targeting cytotoxic T lymphocyte-associated protein 4 (**CTLA-4**), another checkpoint regulator, promoting T-cell activation and proliferation. - **Cabazitaxel** is a small molecule taxane that disrupts microtubule function, inducing cell cycle arrest and apoptosis in cancer cells. - **Carboplatin** is a small molecule platinum compound that creates DNA crosslinks, triggering apoptosis in rapidly dividing cells. This combination is not a standard, approved regimen; while nivolumab + ipilimumab and cabazitaxel + carboplatin have separately and in pairs been studied or used against cancers such as advanced melanoma, lung cancer, and others[1][2][4][5][8], this specific four-drug combination has not been described as an approved product or formal combination therapy. The intent would be to harness immunotherapy with cytotoxic chemotherapy for treatment-refractory or advanced malignancies, especially in clinical trials for solid tumors.

Other names

nivolumabipilimumabcabazitaxelcarboplatin